{
  "id": "mhgap#risk_safety_e228709c",
  "content": "were provided to evidence review and synthesis teams the evidence.\nto ensure consistency across review teams. Evidence\non effectiveness of interventions was mostly extracted The findings from the qualitative reviews, systematic\nfrom Cochrane Reviews and from other systematic reviews on the use of mhGAP, and case studies, along\nreviews where no Cochrane Review was available. In with quantitative reviews, provided evidence that\ninstances where the reviews identified were found to contributed particularly to GDG discussions on the\n3 https://www.who.int/teams/mental-health-and-substance-use/treatment-care/mental-health-gap-action-programme/evidence-centre\n7\nMental Health Gap Action Programme (mhGAP) guideline for mental, neurological and substance use disorders\nfollowing domains of the GRADE EtD framework: values, quality” evidence, while non-randomized trials and\nhealth equity, equality and non-discrimination, human observational studies provide “low-quality” evidence.\nrights and sociocultural acceptability and feasibility. This baseline quality rating may then be downgraded\nbased on consideration of study design limitations\n2.3.6 Appraising evidence (risk of bias), inconsistency, imprecision, indirectness\nand publication bias. For observational studies, other\nQuantitative evidence\nconsiderations, such as magnitude of effect, could lead\nThe GRADE approach to appraising the quality of\nto upgrading of the rating if there are no limitations\nquantitative evidence was used for all critical outcomes\nthat indicated a need for downgrading. The systematic",
  "metadata": {
    "source": "WHO mhGAP-IG 2023",
    "url": "https://www.who.int/",
    "condition": "General",
    "risk_band": "low",
    "topics": [
      "study",
      "work",
      "risk_safety",
      "management"
    ],
    "is_clinical": true,
    "is_advice": false
  },
  "index_text": "General — Risk Safety were provided to evidence review and synthesis teams the evidence.\nto ensure consistency across review teams. Evidence\non effectiveness of interventions was mostly extracted The findings from the qualitative reviews, systematic\nfrom Cochrane Reviews and from other systematic reviews on the use of mhGAP, and case studies, along\nreviews where no Cochrane Review was available. In with quantitative reviews, provided evidence that\ninstances where the reviews identified were found to contributed particularly to GDG discussions on the\n3 https://www.who.int/teams/mental-health-and-substance-use/treatment-care/mental-health-gap-action-programme/evidence-centre\n7\nMental Health Gap Action Programme (mhGAP) guideline for mental, neurological and substance use disorders\nfollowing domains of the GRADE EtD framework: values, quality” evidence, while non-randomized trials and\nhealth equity, equality and non-discrimination, human observational studies provide “low-quality” evidence.\nrights and sociocultural acceptability and feasibility. This baseline quality rating may then be downgraded\nbased on consideration of study design limitations\n2.3.6 Appraising evidence (risk of bias), inconsistency, imprecision, indirectness\nand publication bias. For observational studies, other\nQuantitative evidence\nconsiderations, such as magnitude of effect, could lead\nThe GRADE approach to appraising the quality of\nto upgrading of the rating if there are no limitations\nquantitative evidence was used for all critical outcomes\nthat indicated a need for downgrading. The systematic Were provided to evidence review and synthesis teams the evidence. to ensure consistency across review teams."
}